Apomorphine (Onapgo) vs SER-252 (PEOZ-apomorphine)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Parkinson's Disease
Shared mechanism: Dopamine receptor (non-ergoline agonist) · full Parkinson's Disease pipeline
Apomorphine (Onapgo)
Marketed by Supernus Pharmaceuticals and partners
NCT02006121 · Phase 3 · completed
The 12-week blinded phase randomized 107 participants to apomorphine or saline placebo, with participants, care providers, investigators, and outcome assessors masked. The primary clinical endpoint was met: apomorphine produced a greater reduction in daily OFF time than placebo, with a reported p-value of 0.0047, although substantial numbers did not complete the blinded phase.
Reported efficacy
Mean Change in Daily OFF Time From Baseline (Start of Blinded Treatment) to the End of Double-blind Phase (Visit 10) Based on Patient Diaries Using MMRM mITT Population (Baseline and 12 weeks): Mean Change in Daily OFF Time From Baseline (Start of Blinded Treatment) to the End of Double-blind Phase (Visit 10) Based on Patient Diaries Using MMRM mITT Population (Baseline and 12 weeks): Apomorphine Hydrochloride -2.61 Hours (95% CI -3.43 to -1.8) vs Placebo -0.75 Hours (95% CI -1.66 to 0.16) (met)
Result source: NCT02006121
SER-252 (PEOZ-apomorphine)
Developed by Serina Therapeutics
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: January 2027 · NCT07422675 (registry estimate)
No aligned efficacy figure on record for this race.
Results for Parkinson's Disease
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Apomorphine (Onapgo) | SER-252 (PEOZ-apomorphine) |
|---|---|---|
| OFF time, change | -2.6 vs -0.8−1.9 vs placeboNCT02006121 | —Not reported |
| ON time without troublesome dyskinesia, change | —Not reported | —Not reported |
| UPDRS Part III, change | —Not reported | —Not reported |
| MDS-UPDRS Part II, change | —Not reported | —Not reported |
OFF time, change
- Apomorphine (Onapgo)
- -2.6 vs -0.8−1.9 vs placeboNCT02006121
- SER-252 (PEOZ-apomorphine)
- —Not reported
ON time without troublesome dyskinesia, change
- Apomorphine (Onapgo)
- —Not reported
- SER-252 (PEOZ-apomorphine)
- —Not reported
UPDRS Part III, change
- Apomorphine (Onapgo)
- —Not reported
- SER-252 (PEOZ-apomorphine)
- —Not reported
MDS-UPDRS Part II, change
- Apomorphine (Onapgo)
- —Not reported
- SER-252 (PEOZ-apomorphine)
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
SER-252 (PEOZ-apomorphine): no structured comparison results are available for Parkinson's Disease.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Apomorphine (Onapgo): 4 of 4 rows · SER-252 (PEOZ-apomorphine): 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Apomorphine (Onapgo) |
|---|---|
| Dropout rate | 22.2% NCT02006121 · Phase 3 · monotherapy · Parkinson's Disease · phase 3 |
| Discontinued due to AEs | 11.1% NCT02006121 · Phase 3 · monotherapy · Parkinson's Disease · phase 3 |
| Serious AEs | 23.5% NCT02006121 · Phase 3 · monotherapy · Parkinson's Disease · phase 3 |
| Most frequent reported AEs | infusion site nodule 46.9% (placebo 0%) nausea 20.4% (placebo 9.4%) somnolence 19.4% (placebo 3.8%) NCT02006121 · Phase 3 · monotherapy · Parkinson's Disease · phase 3 |
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Apomorphine (Onapgo)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Apomorphine (Onapgo)'s landscape · SER-252 (PEOZ-apomorphine)'s landscape